Clinical
Synthetic data: pharma’s next big thing?
Faster, better trials, enhanced pharmacoepidemiology and more ambitious cross-border research are just some of the likely use cases for synthetic data
More Articles
Access and Evidence
An early peek at the FDA’s RWE ‘cookbook’
The FDA is developing guidelines that will help pharma accelerate its adoption of RWE, this is what the industry should know
Multichannel
The rise and rise of digital budgets
Spending on digital promotional and educational activity will continue to rise while promotional budgets for print decline
Medical
Taking clinical trials to the patient
Putting patients at the center of trials in Japan using new tools and approaches
Access and Evidence
The future is bright for RWE in pharma approvals
The FDA and other regulatory bodies are increasingly willing to accept real-world evidence as part of approvals. Pharma is up to the task
Medical
The shift towards digital technology for clinical research
Remote patient participation and trial monitoring can avoid the high risk of hospital visits
Medical
Pharma’s new leaders in field engagement: MSLs
With the whole of pharma in various states of ‘hybridisation’, how can MSLs be supported to deliver enhanced personal service across physical and virtual engagements?
Multichannel
Making medicines sustainable
There’s a new cross-healthcare initiative to cut medicines waste and lower carbon emissions while also improving healthcare equity and serving patients. Pharma will be a key player
Patients and Medical
Reaching Gen-Z
Young people comprise a unique demographic that pharma is not used to serving but new digital tools offer ways to understand, engage and serve them better
Patients and Medical
Helping patients help themselves
Self care offers a new way for health care companies to serve patients better globally and industry collaboration will drive faster progress